

ASX Release

EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

EMVISION APPOINTS DR PHILIP DUBOIS AS NON-EXECUTIVE DIRECTOR

EMVision Medical Devices Limited (ASX: EMV) (“EMVision” or the “Company”), a medical device company focused on the development and commercialisation of portable medical imaging technology, is pleased to advise that today the following board changes become effective:

- **Dr Philip Dubois**, an imaging executive and neuroradiologist has joined the board as an independent Non-executive Director. Dr Dubois is Non-executive Director of Sonic Healthcare (ASX:SHL), former CEO of their imaging division and served as Executive Director from 2001 to 2020. He is also the founder and former CEO and Chairman of Queensland X-Ray. Dr Dubois is currently an Associate Professor of Radiology at the University of Queensland Medical School. He has served on numerous government and radiology group bodies, including the councils of the Royal Australian and New Zealand College of Radiologists and the Australian Medical Association, and as Vice-President of the Australian Diagnostic Imaging Association. Dr Dubois is a Non-executive Director of Magnetica Limited.
- **Consistent with the board’s succession strategy, Ryan Laws** has stepped down from his role as Non-executive Director of the Company as Dr Dubois joins the board during this next stage of growth.

Dr Philip Dubois, commented “It is a privilege to be invited to join the board of this outstanding, innovative Australian healthcare company, which has strong prospects to save lives and enhance early recovery of patients suffering strokes, head injuries, and, in the longer term, a range of other medical conditions. The pace at which this unique technology has been developed to clinical prototype and clinical trials since inception has been impressive to say the least. This is due to the passion and dedication shown by the teams at University of Queensland and at the Princess Alexander hospital, and the wisdom, energy, experience and expertise of the board, executive management team, and the clinical advisory board.”

EMVision’s Chairman, John Keep, commented “We welcome Philip to the board and are thrilled to have an individual of his calibre, experience and international recognition. Philip has played a significant role in Sonic Healthcare’s journey from inception to an industry leader and ASX Top 50 company. We look forward to his contributions to the continued growth and strategic development of EMVision. We thank Ryan for his valuable contribution to the board and Company over the last 3 years, particularly his instrumental role in EMVision’s successful IPO.”

The key terms of Dr Dubois’s director’s remuneration are set out in the following schedule.

KEY TERMS OF ENGAGEMENT AS A NON-EXECUTIVE DIRECTOR

Term: Commencing 29 September 2020

Compensation:

- A A director's fee of \$45,000 per annum, plus superannuation calculated as per the legislative minimum;
- B Subject to shareholder approval, 500,000 options over ordinary shares, with an exercise price of \$3.95 and expiry date of 29 September 2023, with the following vesting conditions: 50% vest 12 months from grant date and 50% vest 24 months from grant date.

Working hours: As much time as is necessary to perform the role as non-executive director.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Michael Wills
Investor & Media Relations
+61 468 385 208
michael@spring-communications.com.au

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 30 researchers is led by co-inventors Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging, along with Professor Stuart Crozier, who created technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$2 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Trophon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.